Search 33,000+ CME courses
Back

University of Chicago School of Medicine

  • Asparaginase
  • Pancreatitis
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma

Building Clinical Capacity for Optimal Asparaginase-Based Treatment in Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma: Approaches in Pediatric, Adult, and Adolescent and Young Adult Patients

Asparaginase is a cornerstone of regimens for acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in pediatric and adult patients. Asparaginase-based therapy is frequently complicated by a distinct spectrum of toxicities, including hypersensitivity reactions, hepatotoxicity, thrombotic events, and pancreatitis, which pose significant clinical management challenges. Further, hypersensitivity and silent inactivation can result in diminished therapeutic effectiveness and poorer outcomes if not appropriately identified and addressed. Novel asparaginase formulations offer alternatives for patients experiencing hypersensitivity to E. coli-derived asparaginase, but these preparations possess distinct pharmacokinetic and immunogenic profiles that necessitate tailored management approaches. The management of ALL/LBL in adolescent and young adults (AYA) is complex, and these patients often have reduced survival due to their unique needs, challenges with transitions of care, and divergent management across different providers and settings. For example, pediatric-inspired regimens improve outcomes in AYA, but adoption has been inconsistent due to logistical complexity, outpatient adherence challenges, and unclear pathways for integrating monitoring and toxicity management into workflows. There is also persistent variability in the implementation of monitoring protocols. To address these challenges, new guidelines specific to the AYA population were recently released. To mitigate barriers and improve outcomes in patients with ALL/LBL, clinicians can benefit from peer-to-peer exchanges to build confidence, model best practices, and discuss practical strategies to achieve goals. Working collaboratively with an outside expert, clinical teams will participate in a 1-hour learning and action planning program to review and enhance their delivery and monitoring of asparaginase-based therapy across diverse patient populations. Educational Partner: Academy for Continued Healthcare Learning (ACHL) Commercial Supporter: Supported by an educational grant from Jazz Pharmaceuticals

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Credit types

AMA PRA Category 1 Credit™Up to 1 credit

MOC types

No MOC

FDA REMS

No

Qualifies for MIPS

Yes
Start Date
October 16, 2026
End Date
October 17, 2026

Target Specialties

No specific specialties targeted.

Pricing

Free

Reported to ACCME by the provider

  • Live
  • Credit · Up to 1 credit
  • When
    Oct 16, 2026

Related courses

See all

Other providers’ courses on the same topic

More from University of Chicago School of Medicine

See all

This provider’s courses closest to this one